Table 1

Correlations of PAK2 and pSer20PAK2 expression with the clinicopathological features of primary gastric cancer
Features No. of cases PAK2 expression P pSer20PAK2 P
High (%) Low (%) High (%) Low (%)
Age (years) 82 65.32 ± 11.06 64.59 ± 11.88 NS 65.17 ± 11.29 64.99 ± 11.81 NS
Gender
 Male 56 42 (75.00) 14 (25.00) NS 47 (83.93) 9 (16.07) NS
 Female 26 20 (76.92) 6 (23.08) 22 (84.62) 4 (15.38)
Histopathological type
 Intestina type
 pap 3 2 (66.67) 1 (33.33) NS 2 (66.67) 1 (33.33) NS
 tub1 19 15 (78.95) 4 (21.05) 16 (84.21) 3 (15.79)
 tub2 22 16 (72.73) 6 (27.27) 18 (81.82) 4 (18.18)
Diffuse type
 por1 12 8 (66.67) 4 (33.33) NS 10 (83.33) 2 (16.67) NS
 por2 26 21 (80.77) 5 (19.23) 23 (88.46) 3 (11.54)
Tumor depth (pT)
 pT1 ~ pT2 62 42 (67.74) 20 (32.26) 0.022 49 (79.03) 13 (20.97) 0.036
 pT3 ~ pT4 20 20 (100.00) 0 (0) 20 (100.00) 0 (0)
Lymph node metastasis (pN)
 pN0 ~ pN1 66 46 (69.70) 20 (30.30) 0.022 53 (80.30) 13 (19.70) 0.036
 pN2 ~ pN3 16 16 (100.00) 0 (0) 16 (100.00) 0 (0)
Distant metastasis (pM)
 pM0 76 56 (73.68) 20 (26.32) 0.025 63 (82.89) 13 (17.11) 0.038
 pM1 6 6 (100.00) 0 (0) 6 (100.00) 0 (0)
pStage
 I ~ II 59 39 (66.10) 20 (33.90) 0.018 46 (77.97) 13 (33.90) 0.031
 III ~ IV 23 23 (100.00) 0 (0) 23 (100.00) 0 (0)
Lymphatic invasion
 Negative 35 26 (74.29) 9 (25.71) NS 29 (82.86) 6 (17.14) NS
 Positive 47 36 (74.60) 11 (25.40) 40 (85.11) 7 (14.89)
Venous invasion
 Negative 58 42 (72.41) 16 (17.59) NS 49 (84.48) 9 (15.52) NS
 Positive 24 20 (83.33) 4 (16.67) 20 (83.33) 4 (16.67)
Hematogenous recurrence
 Negative 72 55 (76.39) 17 (23.61) NS 61 (84.72) 11 (15.28) NS
 Positive 10 7 (70.00) 3 (30.00) 8 (80.00) 2 (20.00)
Peritoneal recurrence
 Negative 72 55 (76.39) 17 (23.61) NS 61 (84.72) 11 (15.28) NS
 Positive 10 7 (70.00) 3 (30.00) 8 (80.00) 2 (20.00)

Note: ‘NS’ refers to ‘no significant’.

Gao et al.

Gao et al. Diagnostic Pathology 2014 9:55   doi:10.1186/1746-1596-9-55

Open Data